Global Human Vaccines Market to Record Significant Gains Through 2025

July 09, 2020

As per the report titled ‘Global Human Vaccines Market Size, Trends, Opportunities and Growth Potential’, available with Market Study Report LLC, global human vaccines market is expected to register an appreciable growth rate over 2019-2025.

Rising awareness regarding various diseases, increasing approval & launches of new vaccines, growing focus on immunization programs, and favorable government initiatives for vaccine development are the key factors driving the growth of global human vaccines market. Further, development of novel technology-based vaccines by emerging players is expected to expand the business landscape over the forecast period, cites the report.

Request sample copy of this Report:

Based on disease indication, global human vaccines market is categorized into pneumococcal disease, diphtheria tetanus and pertussis (DTP), influenza, meningococcal, human papilloma virus (HPV), hepatitis, mumps measles and rubella (MMR), varicella, rotavirus, and others.

The vaccines developed to combat these diseases are developed to cater two demographics – infants, children & adolescents, and adults. Some of leading vaccines in the industry include Prevnar / Prevnar 13, Vaxigrip, Gardasil / Gardasil 9, Fluzone, Varivax, Flublok, Proquad, Menactra, Pneumovax 23, Fluarix/FluLaval, Havrix/Twinrix/Engerix-B, Varilrix, Adacel, M-M-R®II, Boostrix, Menveo, Bexsero, Cervarix, Shingrix, and Trumenba among others.

Leading organizations in worldwide human vaccines market are Biological E. Limited, Serum Institute of India, Bharat Biotech, Panacea Biotec, Sinovac, Bavarian Nordic, Seqirus, Valneva, Astellas Pharma Inc., Emergent BioSolutions, Mitsubishi Tanabe Pharma, AstraZeneca, Pfizer, Merck, GlaxoSmithKline (GSK), and Sanofi Pasteur.

Chat with us